Dr. Oberley shares his excitement about one of Caris’ standout presentations at ASCO: a breakthrough in digital pathology for early-stage breast cancer. This innovative approach uses advanced algorithms to predict long-term risk, helping determine whether extended endocrine therapy is necessary — or if it can safely be avoided. The impact? More personalized, evidence-based care with less overtreatment.
We also dig into:
- Caris' impressive 37 scientific poster presentations at ASCO 2025
- The growing clinical use of molecular testing to drive research, treatment decisions, and patient stratification in trials
- How the tight collaboration between oncologists and pathologists is fueling advances in digital pathology and risk prediction tools
- The rise of AI-powered predictive algorithms that are not only precise, but far more cost-effective, potentially expanding access to next-gen diagnostics
Dr. Oberley’s vision is clear: by integrating molecular insights with digital tools, we’re entering a new era of precision, personalization, and prevention in cancer care.
☕ Grab your favorite cup of tea and join us for this fascinating ASCO episode of #HITeaWithGrace, where digital pathology meets clinical decision-making.
👉 Don’t forget to like, comment, and subscribe for more conversations that are reshaping health tech and oncology.
#ASCO2025 #HITeaWithGrace #DigitalPathology #BreastCancer #PrecisionOncology #MolecularTesting #AIinHealthcare #PredictiveAlgorithms #EndocrineTherapy #CarisLifeSciences #CancerCareInnovation #ClinicalResearch #WomenInHealthIT